Immunotherapy Stocks List
|2019-09-20||BCTXF||20 DMA Support||Bullish|
|2019-09-20||BCTXF||Fell Below 50 DMA||Bearish|
|2019-09-20||CMVLF||Narrow Range Bar||Range Contraction|
|2019-09-20||GLAXF||Narrow Range Bar||Range Contraction|
|2019-09-20||GNBT||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2019-09-20||HGEN||Crossed Above 20 DMA||Bullish|
|2019-09-20||HGEN||Pocket Pivot||Bullish Swing Setup|
|2019-09-20||HGEN||MACD Bullish Signal Line Cross||Bullish|
|2019-09-20||IMUC||Crossed Above 20 DMA||Bullish|
|2019-09-20||NWBO||Narrow Range Bar||Range Contraction|
|2019-09-20||NWBO||20 DMA Support||Bullish|
Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.